Who are we?


Signup for

Online registration

Log in to register
your trial

Search a trial




van CCT (UK)

van CCT (UK)

Erlotinib and chemotherapy for advanced lung cancer. The NVALT-17 study

- candidate number16152
- NTR NumberNTR4410
- ISRCTNISRCTN no longer applicable
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR22-jan-2014
- Secondary IDs2013-004303-39 EudraCT number
- Public TitleErlotinib and chemotherapy for advanced lung cancer. The NVALT-17 study
- Scientific TitleA randomized phase III study of erlotinib compared to intercalated erlotinib with cisplatinum pemetrexed as first-line therapy for advanced EGFR mutated non-small-cell lung cancer. The NVALT-17 study
- hypothesisThe combination of cisplatin-pemetrexed-erlotinib is superior to standard of care erlotinib monotherapy as first line treatment in prolonging progression free survival in patients with advanced NSCLC whose tumors harbor an EGFR mutation.
- Healt Condition(s) or Problem(s) studiedEGFR mutation, Non small cell lung cancer (NSCLC)
- Inclusion criteria Histologically/cytologically proven stage III or IV NSCLC. Tumor treatment-naive. Documented activating EGFR mutation in exon 18, 19 or exon 21. Measurable disease. Age ≥ 18 years. Males and females. ECOG Performance Status of 0 3. Life expectancy > 12 weeks. Adequate contraception for females of childbearing potential. Adequate contraception for male participants.
- Exclusion criteria Documented brain metastasis. Concomitant treatment with experimental medicines, potent CYP3A4 inhibitors or inducers. Previous cytotoxic chemotherapy for lung cancer less than 2 years before study entry. For curatively treated lung cancer: (adjuvant) chemotherapy or chemo-radiotherapy less than 12 month prior to the study entry. Pregnancy or lactation.
- mec approval receivedyes
- multicenter trialyes
- randomisedyes
- masking/blindingNone
- controlActive
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 1-mrt-2014
- planned closingdate1-jan-2019
- Target number of participants150
- InterventionsTreatment with erlotinib or cisplatin-pemetrexed-erlotinib.
- Primary outcomeProgression free survival.
- Secondary outcomeObjective response rate and disease control rate, overall survival, safety.
- TimepointsContinuously.
- Trial web site
- statusplanned
- Sponsor/Initiator NVALT
- Funding
(Source(s) of Monetary or Material Support)
NVALT Oncology
- Publications
- Brief summaryObjectives: Primary: To compare progression-free survival (PFS) between erlotinib alone and cisplatin-pemetrexed-erlotinib in patients with EGFR mutated NSCLC locally advanced and metastatic disease stage IIIB and IV. Secondary: To characterize toxicities of both treatment regimen, tumor response, quality of life, duration of tumor response and overall survival and correlate baseline cMet status with overall survival. Study design Multicenter randomized open phase III parallel group study. Patient will be randomly allocated to either: Control Arm: erlotinib 150 mg/day days until disease progression. A treatment cycle of erlotinib is described a 21 day usage of the treatment. Experimental Arm: 4 cycles of cisplatin 75 mg/m2 and pemetrexed 500 mg/m2 on Day 1 plus erlotinib 150 mg/day days 2-16 every 21 days. After 4 cycles of chemotherapy, patients will continue with maintenance pemetrexed 500mg/m2 on Day 1 plus erlotinib 150 mg/day days 2-16 every 21 days until disease progression. Treatment duration: till disease progression. Approx. 150 patients. Population: Patients with locally advanced or metastatic EGFR mutated NSCLC, tumor treatment-naive. Age 18 years and above. Primary variable variabele: Progression free survival. Secondary variabeles: Objective response rate and disease control rate, overall survival, safety.
- Main changes (audit trail)
- RECORD22-jan-2014 - 9-mei-2014

  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar